Cargando…

A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology

The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) we...

Descripción completa

Detalles Bibliográficos
Autores principales: Athanasiou, Alcibiade, Tennstedt, Pierre, Wittig, Anja, Huber, Ramy, Straub, Oliver, Schiess, Ralph, Steuber, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589165/
https://www.ncbi.nlm.nih.gov/pubmed/34767586
http://dx.doi.org/10.1371/journal.pone.0259093
_version_ 1784598637914882048
author Athanasiou, Alcibiade
Tennstedt, Pierre
Wittig, Anja
Huber, Ramy
Straub, Oliver
Schiess, Ralph
Steuber, Thomas
author_facet Athanasiou, Alcibiade
Tennstedt, Pierre
Wittig, Anja
Huber, Ramy
Straub, Oliver
Schiess, Ralph
Steuber, Thomas
author_sort Athanasiou, Alcibiade
collection PubMed
description The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP.
format Online
Article
Text
id pubmed-8589165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85891652021-11-13 A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology Athanasiou, Alcibiade Tennstedt, Pierre Wittig, Anja Huber, Ramy Straub, Oliver Schiess, Ralph Steuber, Thomas PLoS One Research Article The objective was to determine the prognostic utility of a new biomarker combination in prostate cancer (PCa) patients undergoing Radical Prostatectomy (RP). Serum samples and clinical data of 557 men who underwent RP for PCa with pathological stage (pT) <3 at Martini Clinic (Hamburg, Germany) were used for analysis. Clinical Grade Group and clinical stage was determined using biopsy samples while tumor marker concentrations were measured in serum using immunoassays. The prognostic utility of the proposed marker combination was assessed using Cox proportional hazard regression and Kaplan-Meier analysis. The performance was compared to the Cancer of the Prostate Risk Assessment (CAPRA) score in the overall cohort and in a low-risk patient subset. A multivariable model comprising fibronectin 1, galectin-3-binding protein, lumican, matrix metalloprotease 9, thrombospondin-1 and PSA together with clinical Grade Group (GG) and clinical stage (cT) was created. The proposed model was a significant predictor of biochemical recurrence (BCR) (HR 1.29 per 5 units score, 95%CI 1.20–1.38, p<0.001). The Kaplan-Meier analysis showed that the proposed model had a better prediction for low-risk disease after RP compared to CAPRA (respectively 5.0% vs. 9.1% chance of BCR). In a pre-defined low risk population subset, the risk of BCR using the proposed model was below 5.2% and thus lower when compared to CAPRA = 0–2 (9%), GG<2 (7%) and NCCN = low-risk (6%) subsets. Additionally, the proposed model could significantly (p<0.001) discriminate patients with adverse pathology (AP) events at RP from those without. In conclusion, the proposed model is superior to CAPRA for the prediction of BCR after RP in the overall cohort as well as a in a pre-defined low risk patient population subset. It is also significantly associated with AP at RP. Public Library of Science 2021-11-12 /pmc/articles/PMC8589165/ /pubmed/34767586 http://dx.doi.org/10.1371/journal.pone.0259093 Text en © 2021 Athanasiou et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Athanasiou, Alcibiade
Tennstedt, Pierre
Wittig, Anja
Huber, Ramy
Straub, Oliver
Schiess, Ralph
Steuber, Thomas
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_full A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_fullStr A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_full_unstemmed A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_short A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
title_sort novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589165/
https://www.ncbi.nlm.nih.gov/pubmed/34767586
http://dx.doi.org/10.1371/journal.pone.0259093
work_keys_str_mv AT athanasioualcibiade anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT tennstedtpierre anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT wittiganja anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT huberramy anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT strauboliver anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT schiessralph anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT steuberthomas anovelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT athanasioualcibiade novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT tennstedtpierre novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT wittiganja novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT huberramy novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT strauboliver novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT schiessralph novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology
AT steuberthomas novelserumbiomarkerquintetrevealsaddedprognosticvaluewhencombinedwithstandardclinicalparametersinprostatecancerpatientsbypredictingbiochemicalrecurrenceandadversepathology